Division of Oncology, Department of Internal Medicine, Medical University of Graz (MUG), Austria.
Research Unit for Non-coding RNAs and Genome Editing, Medical University of Graz (MUG), Austria.
Mol Oncol. 2019 Jan;13(1):46-60. doi: 10.1002/1878-0261.12404. Epub 2018 Dec 3.
Altered expression levels of the long noncoding RNA (lncRNA) nuclear-enriched abundant transcript 1 (NEAT1) have been reported in different types of cancer. More than half of the NEAT1 studies in cancer have been published within the last 2 years. In this review, we discuss very recent developments and insights into NEAT1 contribution to carcinogenesis. Summarizing the literature, it becomes obvious that NEAT1 is a lncRNA highly de-/upregulated in a variety of cancer entities, in which it primarily acts as a competing endogenous RNA (ceRNA) which sponges tumor-suppressive microRNA (miRNA). The sponged miRNA lose their ability to degrade, silence, or hamper translation of their downstream-mostly oncogenic-target transcripts, ultimately promoting carcinogenesis. This role of NEAT1 function in tumorigenesis suggests it may be a prognostic biomarker as well as potential therapeutic target, pending the completion of further studies into the underlying mechanisms.
长链非编码 RNA(lncRNA)核丰富转录本 1(NEAT1)的表达水平改变已在不同类型的癌症中报道。在癌症中,超过一半的 NEAT1 研究是在过去 2 年内发表的。在这篇综述中,我们讨论了 NEAT1 对致癌作用的最新发展和见解。总结文献,很明显 NEAT1 是一种在多种癌症实体中高度下调/上调的 lncRNA,主要作为竞争性内源 RNA(ceRNA),可吸收肿瘤抑制性 microRNA(miRNA)。被吸收的 miRNA 失去了降解、沉默或阻碍其下游致癌靶转录物翻译的能力,最终促进了癌症的发生。NEAT1 在肿瘤发生中的这种功能作用表明,它可能是一个预后生物标志物,也是一个潜在的治疗靶点,但需要进一步研究其潜在机制。